Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
15
Frequently Asked Questions
What is Market Cap of NeuroSense Therapeutics Ltd?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. NeuroSense Therapeutics Ltd market cap is $29.03M.
What is the 52-week high for NeuroSense Therapeutics Ltd?
52 week high is the highest price of a stock in the past 52 weeks, or one year. NeuroSense Therapeutics Ltd 52 week high is $2.60 as of September 07, 2025.
What is the 52-week low for NeuroSense Therapeutics Ltd?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. NeuroSense Therapeutics Ltd 52 week low is $0.80 as of September 07, 2025.
What is NeuroSense Therapeutics Ltd stock price today?
NeuroSense Therapeutics Ltd stock price today is $1.18.
What was NeuroSense Therapeutics Ltd stock price yesterday?
NeuroSense Therapeutics Ltd stock price yesterday was $1.10.
What is the PE ratio of NeuroSense Therapeutics Ltd?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. NeuroSense Therapeutics Ltd’s P/E ratio is -2.02.
What is the Price-to-Book ratio of NeuroSense Therapeutics Ltd?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. NeuroSense Therapeutics Ltd P/B ratio is 10.6115.
What is the 50-day moving average of NeuroSense Therapeutics Ltd?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. NeuroSense Therapeutics Ltd 50-day moving average is $1.58.
How many employess does NeuroSense Therapeutics Ltd has?